(Total Views: 435)
Posted On: 02/23/2017 8:21:59 AM
Post# of 72440
Well ok I screwed that conversion up. Here is the correction. It's even better than my screw up made it look. Very little systemic exposure.
" In comparison, based on a previously completed and successful Phase 2b clinical trial of Brilacidin in the treatment of serious skin infections, maximum concentrations of the drug in plasma administered by intravenous (iv) dosing, at 0.6 mg/kg and 0.8 mg/kg, were approximately 9,000 ng/mL and 12,000 ng/mL, respectively."
" In comparison, based on a previously completed and successful Phase 2b clinical trial of Brilacidin in the treatment of serious skin infections, maximum concentrations of the drug in plasma administered by intravenous (iv) dosing, at 0.6 mg/kg and 0.8 mg/kg, were approximately 9,000 ng/mL and 12,000 ng/mL, respectively."
(4)
(0)Scroll down for more posts ▼
